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with MM presenting with dialysis-requiring severe RF may improve their renal func­
tion and discontinue dialysis. Unfortunately, our results are inferior to the literature 
data according to which up to 50% of patients become independent of dialysis.
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Background: It is known that diffuse large-B-cell lymphoma (DLBCL) is a clinically 
heterogeneous entity. The most important clinical predictor of survival is the 
International Prognostic Index, which does not provide information regarding the het­
erogeneous biology of tumors. Two major subtypes of DLBCL have been identified by 
gene expression profiling (GEP) and classified by cell o f origin into germinal center B- 
cell-like (GCB) and activated B-cell-like (ABC). CEP has become a reliable method for 
predicting the outcome of patients with DLBCL treated with E-CHOP chemotherapy. 
However, that its not easily applicable in clinical practise. Several IHC algorithms have 
been developed to assign patients into GCB and non-GCB/ABC subtypes.
Methods: We retrospectively analyzed 142 patients diagnosed ofde novo DLBCL from 
1999 to 2017 at our Hospital treated with chemoimmunotherapy. DLBCL was classified 
using the Hans algorithm into GCB and non-GCB subtypes. The primary end point 
was progression-free survival (PFS) according to the Hans algorithm, that it was esti­
mated by the Kaplan-Meier method.
Results: The percentage of GCB and non-GCB subtypes was 54% and 46%, respec­
tively. After a median follow-up of 37 months, the median progression-free survival 
was 100 months in the global population. No significant differences were found in PFS, 
although there was a trend to favor CGB subtype (PFS at 24 months 70% in CGB group 
and 59% in non-CGB group, with a median of 60 months in non-CGG and not reached 
in CGB group, p =  0.177). Despite of being a retrospective study and the low median 
follow-up of patients, in CGB subtype there was a trend towards better overall survival 
(OS) (2-year OS: 72% vs. 68%), not statistically significant (p — 0.661).
Conclusions: In our study there is a lack of evidence supporting the use of the Hans 
algorithm for stratifying patients into distinct prognostic groups, probably due to the 
low median follow-up. Rather, GEP remains the preferred method for predicting prog­
nosis. IHQ for subclassification of DLBCL is feasible and reproducible, but the harmo­
nization of techniques and centralized consensus review is necessary.
Legal entity responsible for the study: Laura Galvez Carvajal.
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Background: Over the past decades, special attention has been paid to study of quality 
of life (QoL) indicators in hematological patients receiving chemotherapy (CT). 
Nowadays QoL is conceptually viewed as an important complement to traditional 
objective evaluation measures. Aim. To assess QoL in patients with acute leukemia 
(AL) depending on the presence of concomitant ischemic heart disease (1HD) during 
the induction CT.
Methods: Our study involved 83 patients with newly diagnosed AL, of which 19 were 
lymphoblastic, 64-m yeloid leukemia, aged 16-72,43 (51.8%) men, 40 (48.2%) 
women, according to ECOG l-II. Patients received standard induction CT. According 
to concomitant IFID patients were divided into groups: I (n — 47) - AL without cardio­
logical diseases; II (n  =  36) - AL with concomitant IHD. Patients were evaluated using 
SF-36 questionnaire to calculate physical and mental health components before treat­
ment and after 2 induction courses of CT reaching remission.
Results: The indicators of physical and mental QoL components in patients of both 
groups before CT were significantly lower compared with healthy respondents. After 
reaching the remission in patients of group I, all QoL parameters improved, with the 
exception of bodily pain and social functioning. The average physical status indicators 
in patients of groups I and II did not significantly change. At the same time, the psycho­
logical status of patients improved: in group I in 1.5 times (40.9±2.25 vs 27.1±2.77 
before CT, p <  0.05), in group II - in 1.3 times (37.3±2.82 vs 28.3±2.37 before CT; 
p < 0.05). Minimum values of all scales after CT were characteristic for patients with 
concomitant IHD in group II. Differences between groups were not statistically signifi­
cant in all scales, except for the index of physical activity (41.7 ±  1.36 vs 46.6± 2.02;
p <  0.05). However, in comparison with the data of practically healthy respondents, 
QoL of patients with AL after CT remained significantly lower.
Conclusions: The QoL evaluation in patients with .AL with comorbid IHD during 
induction CT is an important component o f the management of oncological patients, 
which allows individualizing the approach to each patient in the presence of this type of 
syntropy.
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Background: Nowadays, there are different guidelines in diagnostics and PET-guided 
treatment of lymphomas. But questions about benefits and predictive role of PET-CT 
in pts with early-stage Hodgkin lymphoma (HL) still remain debatable. Here we report 
results of Ukrainian multicenter retrospective study about the role of PET-CT in early- 
stage HL pts.
Methods: 56 patients, with stages I-II, were registered in the study between August 
2012 and Feb 2018 in 9 Ukrainian hematological centers. Metabolic PET-CT imaging 
was performed according to standard protocols. The threshold of positivity was set for 
a residual uptake higher than the liver background (Deauville score (DS) 4and 5). 
Patients were treated with ABVD or BEACOPPesc regimens based on risk group. The 
primary endpoint was event-free survival (EFS), defined as disease progression or death 
from HL.
Results: Median age of patients at diagnosis was 29 years (range 18-50), 16 (28,5%) 
male and 40 (71,5%) pts were female. Bulky disease (>  10 cm in any dimension) were 
presented in 6/56 (10,7%) of pts, B symptoms - in 16/56 (28,5%) and extranodal disease 
had 4/56 (7%). Median follow-up was 24 months from diagnosis. Interim PET (PET2) 
was performed in 50 pts at 15.5 ± 3  days (range, 5-26) after 2xABVD or 2xBEACOPP 
esc cycles. Interim PET-CT was assessed as DS 1-2 in 34 patients (60,7%), DS 3 in 11 
(19,6%), DS 4-5 in 5 pts (8,8%). In total, disease progression was documented in 5/56 
(9%). Among them, 2/5 (40%) patient were PET2-positive (PET24-) and 3/5 (60%) 
PET2-negative (PET2-), (p >  0.05). There were no registered deaths from the refractory 
disease. We did not find any significant difference between EFS rate in pts with PET24- 
vs PET2- (log-rank test, p =  0.4). 47 pts have proceeded for end-of-treatment PET-CT 
(PET3). Results showed 3/47 pts (6,3%) were PET3+ and PET3- were 44/47 (93,7%),
(p <  0,05). EFS was compared and assessed depending on DS. Achieved rate of 3-year 
EFS in pts with PET3 DS 1-2, DS 3 and DS 4-5 were 94,4%, 50% and 0%, respectively
(p < 0.006).
Conclusions: End o f treatment PET-CT plays an important role in patients with early- 
stage HL and could be a beneficial prognostic factor. However, there is still need for 
prospective confirmation of interim PET-CT as a prognostic factor.
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Background: Treatment options and outcomes for multiple myeloma (MM) pts were 
greatly changed over the last 10 years. Treatment accordingto different age groups 
requires careful consideration o f the balance between maximizing efficacy and accept­
able tolerability.
Methods: 100 pts ( median age: 63, range 34-80; m: 63, f: 37) were registered in NCI 
from Jan 2006 to Jan 2018.19% (19/100) o f patients received M2, MP, DAV therapy 
(groupl), 46% (46/100) - thalidomide-based (group2) and 35% (35/100) -Pi-based 
regimens (group3). In 28% patients t(4:14), dell3, and dell7pl3] were assessed. The 
primary endpoint was EFS and OS.
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